IDX-184
IDX-184 is an antiviral drug which was developed as a treatment for hepatitis C, acting as a NS5B RNA polymerase inhibitor. While it showed reasonable effectiveness in early clinical trials it did not progress past Phase IIb. However research using this drug has continued as it shows potentially useful activity against other emerging viral diseases such as Zika virus, and coronaviruses including MERS, and SARS-CoV-2.
Q846227
antiviral drug
Concept
Q154869
hepatitis C
Concept
Q24766653
NS5B
MISC
Q272631
RNA polymerase
Concept
Q30612
clinical trial
Concept
Q202864
Zika virus
Concept
Q89469904
coronavirus
Concept
Q16654806
MERS
Concept
Q82069695
SARS-CoV-2
Concept
Q27260574
IDX-184
UNK
-184^^http://www.w3.org/2001/XMLSchema#decimal
-184
NUMBER
+5^^http://www.w3.org/2001/XMLSchema#decimal
5
NUMBER
-2^^http://www.w3.org/2001/XMLSchema#decimal
-2
NUMBER
subclass of